Intensity Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of cancer drugs to treat solid tumors. The company's lead product candidate is INT230-6, which is in Phase 2 clinical trial for the treatment of refractory solid tumors; and pancreatic, colon, bile duct, squamous cell carcinoma, sarcoma, breast, and liver cancers. It has a collaboration agreement with Merck Sharpe & Dohme Corp. to evaluate the combination of INT230-6 and Keytruda in patients with advanced pancreatic, colon, squamous cell, and bile duct malignancies; Bristol-Myers Squibb Company to evaluate the combination of INT230-6 with Yervoy in patients with advanced liver, breast, and sarcoma cancers; and Ottawa Hospital Research Institute and the Ontario Institute of Cancer Research to study INT230-6 in a randomized controlled neoadjuvant phase II study in women with early-stage breast cancer. The company was founded in 2012 and is headquartered in Westport, Connecticut.
Intensity Therapeutics, Inc. (INTS) - Company Outlook
Company Outlook
| Year | Receivables | Debt | Liabilities | Assets | Current Assets |
|---|---|---|---|---|---|
| 2023 | -8,398,000 | 4.13 M | 17.3 M | 15.46 M | |
| 2022 | 62.3 K | 3.18 M | 16.85 M | 1.76 M | 1.45 M |
| 2021 | 51.26 K | -2,196,555 | 13.9 M | 5.22 M | 4.73 M |
| 2020 | 53.81 K | -8,818,611 | 11.71 M | 10.15 M | 9.63 M |
| 2019 | 21.93 K | -3,568,568 | 11.31 M | 8.93 M | 8.65 M |